Corcept Therapeutics (HAM:HTD) Non Operating Income: €0.0 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:HTD Corcept Therapeutics Inc HAM:HTD
85 GF Score
Price €79.12
GF Value €54.33
! 8 Warning Signs
View Full Analysis

What is Corcept Therapeutics Non Operating Income?

Corcept Therapeutics HAM:HTD -2.44% 85 Non Operating Income is €0.0 Mil as of Mar. 2026. GuruFocus rates HAM:HTD with a GF Score™ of 85/100 and a GF Value™ of €54.33. The stock has 8 warning signs investors should review.

Non Operating Income is income or expense that comes from miscellaneous sources. Corcept Therapeutics's Non Operating Income for the three months ended in Mar. 2026 was €0.0 Mil. Its Non Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was €0.0 Mil.

Corcept Therapeutics Non Operating Income Related Terms

Corcept Therapeutics Non Operating Income Historical Data

* Premium members only.

The historical data trend for Corcept Therapeutics's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corcept Therapeutics Non Operating Income Chart

Corcept Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Non Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Corcept Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Non Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
HAM:HTD
85GF Score
Corcept Therapeutics Inc HAM:HTD
Non Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Corcept Therapeutics Non Operating Income Calculation

Non Operating Income is income or expense that comes from miscellaneous sources.

Non Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Non Operating Income →
What does a Non Operating Income of €0.0 Mil mean?
Corcept Therapeutics (HAM:HTD) has a Non Operating Income of €0.0 Mil as of Mar. 2026. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Corcept Therapeutics and its competitors.
Is Corcept Therapeutics' Non Operating Income too high?
Corcept Therapeutics' current Non Operating Income is €0.0 Mil. Overall, Corcept Therapeutics has a GF Score™ of 85/100, reflecting its overall financial health beyond just this single metric.
How does Corcept Therapeutics' Non Operating Income compare to APGE and KRYS?
Corcept Therapeutics' Non Operating Income of €0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Non Operating Income for a Biotechnology company?
A good Non Operating Income depends on the Biotechnology industry context. However, Non Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Non Operating Income mean?
A high Non Operating Income can signal that a stock is expensive relative to its fundamentals. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Corcept Therapeutics and its competitors. Corcept Therapeutics's current Non Operating Income is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corcept Therapeutics stock overvalued right now?
Corcept Therapeutics (HAM:HTD) has a current Non Operating Income of €0.0 Mil. The stock's GF Value™ is €54.33, compared to a current price of €79.12 — trading 45.6% above its estimated fair value. The current Non Operating Income is €0.0 Mil. Corcept Therapeutics' overall GF Score™ is 85/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Non Operating Income calculated?
Non Operating Income is calculated from a company's financial statements. For Corcept Therapeutics (HAM:HTD), the current Non Operating Income is €0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Corcept Therapeutics (HAM:HTD) Overvalued in 2026?

Based on GuruFocus' analysis, Corcept Therapeutics stock appears to be overvalued. The current stock price of €79.12 is trading 45.6% above its estimated GF Value™ of €54.33.

Key valuation signals for HAM:HTD:

  • Non Operating Income: €0.0 Mil
  • GF Value™: €54.33 vs. price of €79.12 (45.6% above fair value)
  • GF Score™: 85/100 with 8 warning signs

No single metric tells the full story. See the HAM:HTD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Corcept Therapeutics Business Description

Address 101 Redwood Shores Parkway, Redwood City, CA, USA, 94065
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
85GF Score

Get the complete analysis for HAM:HTD

Non Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€79.12
Price
€54.33
GF Value